查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1387290

症狀性多重診斷市場報告：到2030年的趨勢、預測與競爭分析

Syndromic Multiplex Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

症狀性多重診斷的趨勢和預測

到2030年，全球症狀性多重診斷市場預計將達到 42.5 億美元，2024年至2030年年複合成長率為 7.5%。該市場的主要促進因素是感染疾病的日益普及、分子診斷技術的日益採用以及對準確、快速結果和快速獲得治療的需求不斷成長。全球症狀性多重診斷市場的未來充滿希望，醫院和診斷實驗室市場存在商機。

症狀性多重診斷市場洞察

Lucintel 預測，在預測期內，消化器官系統系統將繼續佔據更大的佔有率，因為它有助於識別引起胃腸炎和食物中毒等疾病的病原體。

在這個市場中，由於醫院進行了大量的診斷測試，預計醫院仍將是最大的細分市場。

由於醫療保健支出不斷增加，對早期準確診斷的需求不斷增加，以及各種傳染性和非傳染性疾病的盛行率不斷增加，北美在預測期內可能仍然是最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1.細分市場中最有前途和高成長的機會為何？
  • Q.2.哪個產業將以更快的速度成長？理由為何？
  • Q.3.哪些地區未來會出現更快的成長？理由為何？
  • Q.4.影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5.這個市場的商業風險和競爭威脅為何？
  • Q.6.這個市場有哪些新趨勢？理由為何？
  • Q.7.市場客戶需求有何改變？
  • Q.8.該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10.該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去五年發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球症狀性多重診斷市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球症狀性多重診斷市場趨勢（2018-2023）與預測（2024-2030）
  • 依類型分類的全球症狀性多重診斷市場
    • 呼吸系統
    • 消化器官系統
    • 中樞神經系統
    • 其他
  • 依最終用途分類的全球症狀性多重診斷市場
    • 醫院
    • 診斷實驗室
    • 其他

第4章 2018-2030年市場趨勢及預測分析，依地區

  • 依地區分類的全球症狀性多重診斷市場
  • 北美症狀性多重診斷市場
  • 歐洲症狀性多重診斷市場
  • 亞太地區症狀性多重診斷市場
  • 其他地區症狀性多重診斷市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 依類型分類的全球症狀性多重診斷市場成長機會
    • 依最終用途分類的全球症狀性多重診斷市場的成長機會
    • 依地區分類的全球症狀性多重診斷市場成長機會
  • 全球症狀性多重診斷市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球症狀性多重診斷市場的產能擴張
    • 全球症狀性多重診斷市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • BioMerieux
  • Qiagen
  • DiaSorin SpA
  • Applied BioCode
  • Akonni Biosystems
  • Thermo Fisher Scientific
  • Abbott Laboratories
  • Accelerate Diagnostic
  • Becton and Dickinson
  • Hologic
簡介目錄

Syndromic Multiplex Diagnostic Trends and Forecast

The future of the global syndromic multiplex diagnostic market looks promising with opportunities in the hospitals and diagnostics laboratories markets. The global syndromic multiplex diagnostic market is expected to reach an estimated $4.25 billion by 2030 with a CAGR of 7.5% from 2024 to 2030. The major drivers for this market are increasing prevalence of infectious disease, rising adoption of molecular diagnostic techniques, and growing demand for accurate and rapid results and quick access to the treatment.

A more than 150-page report is developed to help in your business decisions.

Syndromic Multiplex Diagnostic by Segment

The study includes a forecast for the global syndromic multiplex diagnostic by type, end use, and region.

Syndromic Multiplex Diagnostic Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Respiratory
  • Gastrointestinal
  • Central Nervous System
  • Others

Syndromic Multiplex Diagnostic Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Diagnostics Laboratories
  • Others

Syndromic Multiplex Diagnostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Syndromic Multiplex Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies syndromic multiplex diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the syndromic multiplex diagnostic companies profiled in this report include-

  • Biomerieux
  • Qiagen
  • Diasorin S.P.A
  • Applied Biocode
  • Akonni Biosystems
  • Thermo Fisher Scientific
  • Abbott Laboratories
  • Accelerate Diagnostic
  • Becton and Dickinson
  • Hologic

Syndromic Multiplex Diagnostic Market Insights

Lucintel forecasts that gastrointestinal will remain the larger segment over the forecast period as it helps in identifing pathogens responsible for diseases like gastroenteritis and foodborne illnesses.

Within this market, hospitals is expected to remain the largest segment due to the high volume of diagnostic tests performed in hospitals.

North America will remain the largest region during the forecast period due to rising healthcare expenditure, growing demand for early and accurate diagnosis, and increasing prevalence of various communicable or non-communicable diseases.

Features of the Global Syndromic Multiplex Diagnostic Market

Market Size Estimates: Syndromic multiplex diagnostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Syndromic multiplex diagnostic market size by type, end use, and region in terms of value ($B).

Regional Analysis: Syndromic multiplex diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, end uses, and regions for the syndromic multiplex diagnostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the syndromic multiplex diagnostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the syndromic multiplex diagnostic market size?

Answer: The global syndromic multiplex diagnostic market is expected to reach an estimated $4.25 billion by 2030.

Q2. What is the growth forecast for syndromic multiplex diagnostic market?

Answer: The global syndromic multiplex diagnostic market is expected to grow with a CAGR of 7.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the syndromic multiplex diagnostic market?

Answer: The major drivers for this market are increasing prevalence of infectious disease, rising adoption of molecular diagnostic techniques, and growing demand for accurate and rapid results and quick access to the treatment.

Q4. What are the major segments for syndromic multiplex diagnostic market?

Answer: The future of the syndromic multiplex diagnostic market looks promising with opportunities in the hospitals and diagnostics laboratories markets.

Q5. Who are the key syndromic multiplex diagnostic market companies?

Answer: Some of the key syndromic multiplex diagnostic companies are as follows:

  • Biomerieux
  • Qiagen
  • Diasorin S.P.A
  • Applied Biocode
  • Akonni Biosystems
  • Thermo Fisher Scientific
  • Abbott Laboratories
  • Accelerate Diagnostic
  • Becton and Dickinson
  • Hologic

Q6. Which syndromic multiplex diagnostic market segment will be the largest in future?

Answer: Lucintel forecasts that gastrointestinal will remain the larger segment over the forecast period as it helps in identifing pathogens responsible for diseases like gastroenteritis and foodborne illnesses.

Q7. In syndromic multiplex diagnostic market, which region is expected to be the largest in next 5 years?

Answer:North America will remain the largest region during the forecast period due to rising healthcare expenditure, growing demand for early and accurate diagnosis, and increasing prevalence of various communicable or non-communicable diseases.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the syndromic multiplex diagnostic market by type (respiratory, gastrointestinal, central nervous system, and others), end use (hospitals, diagnostics laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Syndromic Multiplex Diagnostic Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Syndromic Multiplex Diagnostic Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Syndromic Multiplex Diagnostic Market by Type
    • 3.3.1: Respiratory
    • 3.3.2: Gastrointestinal
    • 3.3.3: Central Nervous System
    • 3.3.4: Others
  • 3.4: Global Syndromic Multiplex Diagnostic Market by End Use
    • 3.4.1: Hospitals
    • 3.4.2: Diagnostics Laboratories
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Syndromic Multiplex Diagnostic Market by Region
  • 4.2: North American Syndromic Multiplex Diagnostic Market
    • 4.2.2: North American Syndromic Multiplex Diagnostic Market by End Use: Hospitals, Diagnostics Laboratories, and Others
  • 4.3: European Syndromic Multiplex Diagnostic Market
    • 4.3.1: European Syndromic Multiplex Diagnostic Market by Type: Respiratory, Gastrointestinal, Central Nervous System, and Others
    • 4.3.2: European Syndromic Multiplex Diagnostic Market by End Use: Hospitals, Diagnostics Laboratories, and Others
  • 4.4: APAC Syndromic Multiplex Diagnostic Market
    • 4.4.1: APAC Syndromic Multiplex Diagnostic Market by Type: Respiratory, Gastrointestinal, Central Nervous System, and Others
    • 4.4.2: APAC Syndromic Multiplex Diagnostic Market by End Use: Hospitals, Diagnostics Laboratories, and Others
  • 4.5: ROW Syndromic Multiplex Diagnostic Market
    • 4.5.1: ROW Syndromic Multiplex Diagnostic Market by Type: Respiratory, Gastrointestinal, Central Nervous System, and Others
    • 4.5.2: ROW Syndromic Multiplex Diagnostic Market by End Use: Hospitals, Diagnostics Laboratories, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Syndromic Multiplex Diagnostic Market by Type
    • 6.1.2: Growth Opportunities for the Global Syndromic Multiplex Diagnostic Market by End Use
    • 6.1.3: Growth Opportunities for the Global Syndromic Multiplex Diagnostic Market by Region
  • 6.2: Emerging Trends in the Global Syndromic Multiplex Diagnostic Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Syndromic Multiplex Diagnostic Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Syndromic Multiplex Diagnostic Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: BioMerieux
  • 7.2: Qiagen
  • 7.3: DiaSorin S.p.A
  • 7.4: Applied BioCode
  • 7.5: Akonni Biosystems
  • 7.6: Thermo Fisher Scientific
  • 7.7: Abbott Laboratories
  • 7.8: Accelerate Diagnostic
  • 7.9: Becton and Dickinson
  • 7.10: Hologic